Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Glaukos Corporation (NYSE:GKOS) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $144.4167.

Several research firms have issued reports on GKOS. Citigroup upped their price target on shares of Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Stifel Nicolaus set a $170.00 price objective on Glaukos in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Wells Fargo & Company increased their target price on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Friday, January 30th.

Insider Transactions at Glaukos

In related news, Director Aimee S. Weisner sold 15,000 shares of Glaukos stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director directly owned 18,806 shares of the company’s stock, valued at $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $135.00, for a total transaction of $675,000.00. Following the completion of the sale, the director directly owned 35,528 shares in the company, valued at approximately $4,796,280. This trade represents a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 55,930 shares of company stock valued at $7,378,263. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

Large investors have recently modified their holdings of the business. First Horizon Corp boosted its holdings in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Glaukos in the 4th quarter worth $28,000. UMB Bank n.a. raised its holdings in Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

NYSE:GKOS opened at $143.53 on Friday. Glaukos has a 52-week low of $73.16 and a 52-week high of $146.75. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The business’s fifty day moving average is $117.10 and its 200 day moving average is $111.39. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of -43.76 and a beta of 0.94.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same period in the previous year, the business posted ($0.22) EPS. The business’s quarterly revenue was up 41.2% on a year-over-year basis. Research analysts predict that Glaukos will post -0.57 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.